Technology Evaluation for Listing of Promising Bio Companies, Only 7 Cases Per Year
Lack of Specialized Institutions Leaves IPO-aspiring Biotech Firms Struggling
Manpower Shortages, Low Fees, and Conflicts of Interest Compound the Problem
The number of technology evaluations—considered the first hurdle for bio-technology companies seeking a special listing on KOSDAQ—is found to be only around seven cases per year. Although there are 16 designated technology evaluation agencies, it is analyzed that only two of them are truly capable of properly assessing new drug development capabilities. Every year, dozens of bio-technology companies attempt to go public, but the majority are inevitably assigned to agencies with relatively lower expertise.
According to the bio industry and relevant authorities as of July 3, the annual average number of special technology evaluations conducted by the two public institutions specializing in new drug assessment—namely, the Korea Health Industry Development Institute and the Korea Research Institute of Bioscience and Biotechnology—remained at around seven cases per year from 2021 through April this year, a period of more than five years. The Korea Health Industry Development Institute handled 17 cases (an annual average of 3.2), while the Korea Research Institute of Bioscience and Biotechnology conducted about four cases per year. Considering that there are dozens of companies seeking listing every year, this performance is regarded as seriously insufficient.
Technology evaluation is the first step in the special technology listing process, which allows companies lacking revenue or profit requirements to qualify for listing based on their technological prowess. A company must receive at least an 'A' rating from one agency and a 'BBB' or higher from another, both assigned by the exchange, in order to apply for preliminary review. There are 16 agencies (reduced from 26 as of March this year), including government-affiliated research and evaluation bodies and private technology credit bureaus (TCBs), but only these two public institutions are considered to have true expertise in bio-technology.
Companies that are not evaluated by these two institutions are referred to agencies that mainly assess patents and intellectual property, or to private TCBs. It has been reported that even a new drug development company that succeeded in technology exports worth trillions of won failed to pass the evaluation threshold because it was assessed by an agency specializing primarily in patent evaluation. This structure means that hundreds of billions of won in financing and the success or failure of a listing may be determined by evaluators who are not familiar with new drugs or clinical trials.
There are also frequent complaints about the allocation of evaluation agencies. The CEO of a bio company that underwent a technology evaluation said, "Because the exchange assigns agencies on a rotating basis, meeting an evaluator who understands new drugs is essentially a matter of luck." Another representative of a new drug development company lamented, "Even if we present global clinical data, we have to explain everything from scratch to an evaluator unfamiliar with new drugs," adding, "The rating depends on the evaluator's understanding, not the value of the technology."
There are three main constraints—manpower, cost, and conflicts of interest—that prevent the two specialized institutions from handling more cases. For each evaluation, about eight internal and external experts are involved for roughly two months, but this evaluation work is an additional duty separate from their main research and business activities. After deducting indirect costs and external advisors' fees, the approximately 20 million won fee per evaluation leaves virtually nothing for the institution itself.
There is also the paradox that the more specialized an institution is, the more likely it is to be excluded from evaluation. Public research institutions cannot evaluate companies with which they have technology transfer or joint research relationships due to conflicts of interest, and many Korean bio companies are founded by researchers, so this applies to a significant number of them. Since evaluation performance does not count toward institutional assessment, there is little incentive for these institutions to take on such work. One evaluation agency official stated, "There needs to be a mechanism for evaluation participation to be recognized as a research institution's achievement."
The exchange is currently working on revising evaluation indicators to segment them by business model. The goal is to divide companies into categories such as diagnostic devices, therapeutics, and NRDOs (New Drug Research and Development Organizations), and prevent distortions where NRDOs, which do not conduct clinical trials themselves, are disadvantaged by clinical trial-based standards. However, there are concerns that such improvements will only enhance the precision of evaluations and will not address the shortage of specialized institutions and their processing capacity.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An official from the exchange said, "Bio companies are preferentially assigned to related specialized institutions, but the number of cases these institutions can handle annually is inherently limited." The exchange began a research project to improve the evaluation system at the end of May, and the results are expected in early September.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.